Friday, February 18, 2022 12:57:41 PM
It looks like all roads lead to " Cannot file the BLA "
If Amarex data is bad - can't file the BLA.
If Samsung was not paid and no longer the manufacturer of LL - can't file the BLA.
If they did not pay the new CRO, they most likely can't file the BLA.
The management appears to think that they can stall forever, the problem is that having no money, not moving forward will have an impact on the stock price, currently the idea of a buyout/partnership is being pushed to convince shareholders to hold. They don't have much time before they have to show their cards and unfortunately they showed them to some extent with the 8K.
They are afraid someone is coming after them to force a bankruptcy and went and hid their IP in a different place.
LH Phase 2 - not happening
NASH Phase 2/Phase 3 - not happening
Brazil current trials - most likely not happening
Pretty soon we will be happy to sell it all for $3, if we can even get that, and mostly because management sabotaged their own efforts.
jmo
If Amarex data is bad - can't file the BLA.
If Samsung was not paid and no longer the manufacturer of LL - can't file the BLA.
If they did not pay the new CRO, they most likely can't file the BLA.
The management appears to think that they can stall forever, the problem is that having no money, not moving forward will have an impact on the stock price, currently the idea of a buyout/partnership is being pushed to convince shareholders to hold. They don't have much time before they have to show their cards and unfortunately they showed them to some extent with the 8K.
They are afraid someone is coming after them to force a bankruptcy and went and hid their IP in a different place.
LH Phase 2 - not happening
NASH Phase 2/Phase 3 - not happening
Brazil current trials - most likely not happening
Pretty soon we will be happy to sell it all for $3, if we can even get that, and mostly because management sabotaged their own efforts.
jmo
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
